A pediatric dosing chart for the influenza drug oseltamivir (Tamiflu) sent by Roche Laboratories Inc. to health care providers last November contained an error and should have indicated a standard dosage of once daily—rather than twice daily—for 10 days, according to a letter from the company.
The erroneous chart, titled “Standard Dosage of the Tamiflu Oral Suspension for Prophylaxis of Influenza in Pediatric Patients,” had accompanied a November letter announcing reports of self-injury and delirium in patients taking Tamiflu.
The letter from Roche said that none of the Tamiflu on the market contains package inserts with the incorrect dosage chart.
Prescribing information is online at www.rocheusa.com/products/tamiflu/pi.pdf